Thus, PD-L1 diagnostic immunohistochemistry (IHC) assays have been approved by the US FDA for assessment of PD-L1 expression on tumor cells and are currently used as biomarkers to guide the selection of patients to receive PD-1/PD-L1 ICBs [13, 14]. Here, PDCD1 is linked to neoplasm.